246 related articles for article (PubMed ID: 31322692)
1. Deep Learning to Assess Long-term Mortality From Chest Radiographs.
Lu MT; Ivanov A; Mayrhofer T; Hosny A; Aerts HJWL; Hoffmann U
JAMA Netw Open; 2019 Jul; 2(7):e197416. PubMed ID: 31322692
[TBL] [Abstract][Full Text] [Related]
2. Deep Learning Using Chest Radiographs to Identify High-Risk Smokers for Lung Cancer Screening Computed Tomography: Development and Validation of a Prediction Model.
Lu MT; Raghu VK; Mayrhofer T; Aerts HJWL; Hoffmann U
Ann Intern Med; 2020 Nov; 173(9):704-713. PubMed ID: 32866413
[TBL] [Abstract][Full Text] [Related]
3. Validation of a Deep Learning Algorithm for the Detection of Malignant Pulmonary Nodules in Chest Radiographs.
Yoo H; Kim KH; Singh R; Digumarthy SR; Kalra MK
JAMA Netw Open; 2020 Sep; 3(9):e2017135. PubMed ID: 32970157
[TBL] [Abstract][Full Text] [Related]
4. Deep Learning to Estimate Biological Age From Chest Radiographs.
Raghu VK; Weiss J; Hoffmann U; Aerts HJWL; Lu MT
JACC Cardiovasc Imaging; 2021 Nov; 14(11):2226-2236. PubMed ID: 33744131
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of the lung cancer risks at which to screen ever- and never-smokers: screening rules applied to the PLCO and NLST cohorts.
Tammemägi MC; Church TR; Hocking WG; Silvestri GA; Kvale PA; Riley TL; Commins J; Berg CD
PLoS Med; 2014 Dec; 11(12):e1001764. PubMed ID: 25460915
[TBL] [Abstract][Full Text] [Related]
6. Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial.
Oken MM; Hocking WG; Kvale PA; Andriole GL; Buys SS; Church TR; Crawford ED; Fouad MN; Isaacs C; Reding DJ; Weissfeld JL; Yokochi LA; O'Brien B; Ragard LR; Rathmell JM; Riley TL; Wright P; Caparaso N; Hu P; Izmirlian G; Pinsky PF; Prorok PC; Kramer BS; Miller AB; Gohagan JK; Berg CD;
JAMA; 2011 Nov; 306(17):1865-73. PubMed ID: 22031728
[TBL] [Abstract][Full Text] [Related]
7. Assessing eligibility for lung cancer screening using parsimonious ensemble machine learning models: A development and validation study.
Callender T; Imrie F; Cebere B; Pashayan N; Navani N; van der Schaar M; Janes SM
PLoS Med; 2023 Oct; 20(10):e1004287. PubMed ID: 37788223
[TBL] [Abstract][Full Text] [Related]
8. Renal-cell carcinoma risk estimates based on participants in the prostate, lung, colorectal, and ovarian cancer screening trial and national lung screening trial.
Lotan Y; Karam JA; Shariat SF; Gupta A; Roupret M; Bensalah K; Margulis V
Urol Oncol; 2016 Apr; 34(4):167.e9-16. PubMed ID: 26602092
[TBL] [Abstract][Full Text] [Related]
9. Association of Inclusion of More Black Individuals in Lung Cancer Screening With Reduced Mortality.
Prosper AE; Inoue K; Brown K; Bui AAT; Aberle D; Hsu W
JAMA Netw Open; 2021 Aug; 4(8):e2119629. PubMed ID: 34427681
[TBL] [Abstract][Full Text] [Related]
10. Association of Nonadherence to Cancer Screening Examinations With Mortality From Unrelated Causes: A Secondary Analysis of the PLCO Cancer Screening Trial.
Pierre-Victor D; Pinsky PF
JAMA Intern Med; 2019 Feb; 179(2):196-203. PubMed ID: 30592477
[TBL] [Abstract][Full Text] [Related]
11. Comparing Lung Cancer Screening Strategies in a Nationally Representative US Population Using Transportability Methods for the National Lung Cancer Screening Trial.
Robertson SE; Joyce NR; Steingrimsson JA; Stuart EA; Aberle DR; Gatsonis CA; Dahabreh IJ
JAMA Netw Open; 2024 Jan; 7(1):e2346295. PubMed ID: 38289605
[TBL] [Abstract][Full Text] [Related]
12. Selection criteria for lung-cancer screening.
Tammemägi MC; Katki HA; Hocking WG; Church TR; Caporaso N; Kvale PA; Chaturvedi AK; Silvestri GA; Riley TL; Commins J; Berg CD
N Engl J Med; 2013 Feb; 368(8):728-36. PubMed ID: 23425165
[TBL] [Abstract][Full Text] [Related]
13. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening.
Katki HA; Kovalchik SA; Berg CD; Cheung LC; Chaturvedi AK
JAMA; 2016 Jun; 315(21):2300-11. PubMed ID: 27179989
[TBL] [Abstract][Full Text] [Related]
14. Comparative analysis of 5 lung cancer natural history and screening models that reproduce outcomes of the NLST and PLCO trials.
Meza R; ten Haaf K; Kong CY; Erdogan A; Black WC; Tammemagi MC; Choi SE; Jeon J; Han SS; Munshi V; van Rosmalen J; Pinsky P; McMahon PM; de Koning HJ; Feuer EJ; Hazelton WD; Plevritis SK
Cancer; 2014 Jun; 120(11):1713-24. PubMed ID: 24577803
[TBL] [Abstract][Full Text] [Related]
15. Bladder cancer risk: Use of the PLCO and NLST to identify a suitable screening cohort.
Krabbe LM; Svatek RS; Shariat SF; Messing E; Lotan Y
Urol Oncol; 2015 Feb; 33(2):65.e19-25. PubMed ID: 25044253
[TBL] [Abstract][Full Text] [Related]
16. Risk prediction models for selection of lung cancer screening candidates: A retrospective validation study.
Ten Haaf K; Jeon J; Tammemägi MC; Han SS; Kong CY; Plevritis SK; Feuer EJ; de Koning HJ; Steyerberg EW; Meza R
PLoS Med; 2017 Apr; 14(4):e1002277. PubMed ID: 28376113
[TBL] [Abstract][Full Text] [Related]
17. OWL: an optimized and independently validated machine learning prediction model for lung cancer screening based on the UK Biobank, PLCO, and NLST populations.
Pan Z; Zhang R; Shen S; Lin Y; Zhang L; Wang X; Ye Q; Wang X; Chen J; Zhao Y; Christiani DC; Li Y; Chen F; Wei Y
EBioMedicine; 2023 Feb; 88():104443. PubMed ID: 36701900
[TBL] [Abstract][Full Text] [Related]
18. Radiologists can visually predict mortality risk based on the gestalt of chest radiographs comparable to a deep learning network.
Weiss J; Taron J; Jin Z; Mayrhofer T; Aerts HJWL; Lu MT; Hoffmann U
Sci Rep; 2021 Oct; 11(1):19586. PubMed ID: 34599265
[TBL] [Abstract][Full Text] [Related]
19. Abnormalities on chest radiograph reported in subjects in a cancer screening trial.
Pinsky PF; Freedman M; Kvale P; Oken M; Caporaso N; Gohagan J
Chest; 2006 Sep; 130(3):688-93. PubMed ID: 16963664
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]